About: Clinical course and end-of-life care in patients who have died after allogeneic stem cell transplantation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical course and end-of-life care in patients who have died after allogeneic stem cell transplantation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical course and end-of-life care in patients who have died after allogeneic stem cell transplantation
Creator	Buchhold, Britta Busemann, Christoph Jülich, Andreas Krüger, William Neumann, Thomas Pink, Daniel Schmidt, Vanessa Schneidewind, Laila Christian, · Schmidt, Andreas
Source	PMC
abstract	PURPOSE: Allogeneic stem cell transplantation may cure approximately 50% of patients, however, a significant part of the other half might benefit from a high-quality palliative care medicine at the end of life. Somatic, psychic and spiritual needs of these patients may differ from those of patients suffering from incurable solid tumours and are not comprehensively evaluated so far. METHODS: To address this question, data from charts of 123 patients who have died after allogeneic stem cell transplantation were extracted. In detail, the time line of the clinical course, the symptoms, the administered drugs and other applied procedures were analysed. RESULTS: Approximately one half of the patients, who have died after stem cell transplantation, did not live more than 5 months. Two-thirds of patients died within 14 months after SCT. 28.5% of the patients could not be discharged after transplantation. However, a significant proportion had a low ECOG-score (0–1) prior to death, indicating a high degree of mobility. Major symptoms were weakness, fatigue and need for aid at daily activities. Severe pain, dyspnoea and obstipation, as known from patients suffering from advanced solid tumours, were rare. In consequence, use of opioids seemed to be less frequent than in patients with solid tumours. Measures of intensive care and i.v.-drug administration were applied to a significant proportion of patients. CONCLUSION: The present investigation indicates that the somatic, psychic and spiritual end-of-life-care after allogeneic stem cell transplantation could be optimised. A significant problem for the transplantation team seems to be the realisation of necessity to switch the curative concept into a palliative ambition. Requirements are a subsequent prospectively conducted investigation and an intensification of cooperation between transplant and palliative care teams.
has issue date	2017-05-27(xsd:dateTime)
bibo:doi	10.1007/s00432-017-2446-y
bibo:pmid	28551769
has license	no-cc
sha1sum (hex)	6dbaab53f243b1a8d9ea07ff7f2b00d24331b1f8
schema:url	https://doi.org/10.1007/s00432-017-2446-y
resource representing a document's title	Clinical course and end-of-life care in patients who have died after allogeneic stem cell transplantation
has PubMed Central identifier	PMC7101727
has PubMed identifier	28551769
schema:publication	J Cancer Res Clin Oncol
resource representing a document's body	covid:6dbaab53f243b1a8d9ea07ff7f2b00d24331b1f8#body_text
is schema:about of	named entity 'stem cell' named entity 'cooperation' named entity 'solid' named entity 'patients' named entity 'stem cell' named entity 'PROBLEM' named entity 'INTENSIFICATION' named entity 'TEAMS' named entity 'TEAM' named entity 'DRUG ADMINISTRATION' named entity 'COOPERATION' named entity 'rare' named entity 'team' named entity 'dyspnoea' named entity 'obstipation' named entity 'opioids' named entity 'solid tumours' named entity 'allogeneic stem cell transplantation' named entity 'allogeneic' named entity '5.7%' named entity 'Microsoft' named entity 'immunosuppressive agents' named entity 'breast cancer' named entity 'cytopenia' named entity 'median survival time' named entity 'catecholamine' named entity 'solid tumours' named entity 'fatigue' named entity 'palliative care' named entity 'chemotherapy' named entity 'allogeneic stem cell transplantation' named entity 'symptom' named entity 'life expectancy' named entity 'nausea' named entity 'antiviral therapy' named entity 'symptom' named entity 'malignancy' named entity 'symptom' named entity 'bone marrow' named entity 'myeloablative' named entity 'lymphoma' named entity 'intensive care' named entity 'palliative care' named entity 'palliative care' named entity 'point of no return' named entity 'pancytopenia' named entity 'haemopoietic' named entity 'Allogeneic stem cell transplantation' named entity 'symptom' named entity 'Deeg' named entity 'palliative' named entity 'extracorporeal membrane oxygenation' named entity 'hospice' named entity 'long-term' named entity 'non-Hodgkin's lymphomas' named entity 'symptom control' named entity 'Intensive care' named entity 'pancytopenia' named entity 'obstipation' named entity 'allogeneic stem cell transplantation' named entity 'anxiolytics' named entity 'immunosuppressive agents' named entity 'laxatives' named entity 'symptom control' named entity 'anaemia' named entity 'metastatic' named entity 'relapse' named entity 'solid tumour' named entity 'lung cancer' named entity 'radiotherapy' named entity 'opioids' named entity 'inpatient admission'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software